{"version":"1.0","provider_name":"South Africa Journal","provider_url":"https:\/\/southafricajournal.com","author_name":"sjadmin","author_url":"https:\/\/southafricajournal.com\/author\/sjadmin-s\/","title":"NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101 - South Africa Journal","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"6dV4SZIThz\"><a href=\"https:\/\/southafricajournal.com\/nrx-pharmaceuticals-lotus-pharmaceuticals-and-alvogen-inc-announce-collaboration-to-develop-and-commercialize-nrx-101\/\">NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/southafricajournal.com\/nrx-pharmaceuticals-lotus-pharmaceuticals-and-alvogen-inc-announce-collaboration-to-develop-and-commercialize-nrx-101\/embed\/#?secret=6dV4SZIThz\" width=\"600\" height=\"338\" title=\"&#8220;NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101&#8221; &#8212; South Africa Journal\" data-secret=\"6dV4SZIThz\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets Lotus Pharmaceuticals will acquire worldwide rights for NRX-101 for S-TRBD and will be responsible for commercialization of NRX-101 in markets outside the US through Lotus\u2019s direct presence in certain Asian [\u2026]","thumbnail_url":"https:\/\/ci6.googleusercontent.com\/proxy\/1Yq5y3CDV1Ihw8onLhpu5RuP1kPkECWoHSdlSOYR1TOYmaDX0IDVUBukQ8pBmL655ZayB7g6C-Dchp2ZQQIEROrH6tB1kZtS2ojz_mpuYXutjejaIwtaDlUXBnRueDvuKTak7-CTZX4=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgyMzUxOCM0MDE1NjIzMDMjNzAwMDEzNTg3"}